Markets are Closed
Company Logo
NVO
Novo Nordisk A/S

Open

64.40

Previous Open

High

64.77

Previous High

Low

63.98

Previous Low

Close

64.64

Previous Close

Volume

2,926,638

Previous Volume

Company Profile

Description

Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

Exchange

New York Stock Exchange

List Date

January 02, 1990

CEO

Lars Fruergaard Jorgensen

Employees

43,161

Related Stocks

BMYLLYPFESNYXLV

Financials

Revenue

17.94B

Earnings

7.72B
20B
17B
13B
10B
6B
2017
2017
2018
2018

Splits

January 08, 20140.20%
December 17, 20070.50%
April 11, 20010.40%

Dividends

April 07, 2020$0.56
August 27, 2019$0.32
April 02, 2019$0.56
August 28, 2018$0.33
April 03, 2018$0.58
August 29, 2017$0.34
April 04, 2017$0.48
August 23, 2016$0.33
March 30, 2016$0.70
March 31, 2015$0.53
April 02, 2014$0.61
April 02, 2013$0.45

Related News

News post image: Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
Feb 05, 2020 @ 16:11
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019....
finance yahoo
News post image: Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Nov 19, 2019 @ 14:23
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases....
finance yahoo
News post image: New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
Nov 19, 2019 @ 13:50
PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make people more – or less – prone to developing type 2 diabetes...
finance yahoo
News post image: Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
Nov 18, 2019 @ 12:46
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same....
finance yahoo
News post image: AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
Nov 15, 2019 @ 14:23
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU....
finance yahoo
News post image: 4 Big Drugmakers to Bet on After a Great Earnings Season
4 Big Drugmakers to Bet on After a Great Earnings Season
Nov 15, 2019 @ 11:41
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry....
finance yahoo
News post image: The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
Nov 14, 2019 @ 15:43
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics...
finance yahoo
News post image: FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Nov 14, 2019 @ 14:44
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes....
finance yahoo
News post image: Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
Nov 13, 2019 @ 18:54
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk...
finance yahoo
News post image: The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Nov 11, 2019 @ 15:32
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J...
finance yahoo